Madeddu, C.; Lai, E.; Neri, M.; Sanna, E.; Gramignano, G.; Nemolato, S.; Scartozzi, M.; Giglio, S.; Macciò, A.
Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics. Int. J. Mol. Sci. 2025, 26, 2232.
https://doi.org/10.3390/ijms26052232
AMA Style
Madeddu C, Lai E, Neri M, Sanna E, Gramignano G, Nemolato S, Scartozzi M, Giglio S, Macciò A.
Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics. International Journal of Molecular Sciences. 2025; 26(5):2232.
https://doi.org/10.3390/ijms26052232
Chicago/Turabian Style
Madeddu, Clelia, Eleonora Lai, Manuela Neri, Elisabetta Sanna, Giulia Gramignano, Sonia Nemolato, Mario Scartozzi, Sabrina Giglio, and Antonio Macciò.
2025. "Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics" International Journal of Molecular Sciences 26, no. 5: 2232.
https://doi.org/10.3390/ijms26052232
APA Style
Madeddu, C., Lai, E., Neri, M., Sanna, E., Gramignano, G., Nemolato, S., Scartozzi, M., Giglio, S., & Macciò, A.
(2025). Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics. International Journal of Molecular Sciences, 26(5), 2232.
https://doi.org/10.3390/ijms26052232
_Kim.png)
